Edgestream Partners L.P. bought a new stake in shares of 10x Genomics (NASDAQ:TXG – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 20,365 shares of the company’s stock, valued at approximately $1,840,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. HighTower Advisors LLC boosted its position in shares of 10x Genomics by 410.7% during the third quarter. HighTower Advisors LLC now owns 85,558 shares of the company’s stock valued at $7,731,000 after purchasing an additional 68,806 shares in the last quarter. Ground Swell Capital LLC bought a new stake in shares of 10x Genomics in the 3rd quarter worth approximately $315,000. Werba Rubin Papier Wealth Management bought a new stake in shares of 10x Genomics in the 3rd quarter worth approximately $347,000. Lido Advisors LLC purchased a new stake in shares of 10x Genomics in the 3rd quarter worth approximately $256,000. Finally, AlphaCore Capital LLC bought a new position in 10x Genomics during the 3rd quarter valued at approximately $200,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.
Analysts Set New Price Targets
TXG has been the topic of several analyst reports. UBS Group lowered their price objective on 10x Genomics from $90.00 to $61.00 and set a “neutral” rating on the stock in a research report on Friday, November 6th. Stephens downgraded shares of 10x Genomics from an “overweight” rating to an “equal weight” rating in a research report on Friday, October 23rd. TD Cowen raised their target price on shares of 10x Genomics from $47.00 to $70.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Canaccord Genuity Group boosted their price target on 10x Genomics from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Finally, Argus initiated coverage on 10x Genomics in a research note on Monday, September 28th. They set a “buy” rating and a $110.00 price target for the company. Five investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $68.40.
10x Genomics Stock Down 9.9%
10x Genomics stock opened at $51.70 on Friday. 10x Genomics has a 52-week low of $15.18 and a 52-week high of $102.81. The firm’s fifty day moving average is $72.86 and its 200 day moving average is $43.45. The company has a market cap of $6.80 billion, a price-to-earnings ratio of -99.42 and a beta of 2.03.
10x Genomics (NASDAQ:TXG – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.12. The company had revenue of $150.67 million for the quarter, compared to analyst estimates of $147.96 million. 10x Genomics had a negative return on equity of 8.19% and a negative net margin of 10.84%. 10x Genomics’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.22) EPS. On average, equities research analysts anticipate that 10x Genomics will post -0.67 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other 10x Genomics news, CEO Serge Saxonov sold 31,000 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $62.90, for a total transaction of $1,949,900.00. Following the transaction, the chief executive officer owned 1,019,249 shares of the company’s stock, valued at approximately $64,110,762.10. This trade represents a 2.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Benjamin Hindson sold 13,818 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $63.02, for a total transaction of $870,810.36. Following the completion of the transaction, the insider directly owned 488,182 shares of the company’s stock, valued at $30,765,229.64. This trade represents a 2.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 190,333 shares of company stock worth $12,604,970. 8.84% of the stock is owned by company insiders.
10x Genomics Company Profile
10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.
Featured Articles
- Five stocks we like better than 10x Genomics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
